Skip to content

The Effects of AFO Heel Height and Stiffness on Gait

The Effects of AFO Heel Height and Stiffness on Gait

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04800484
Acronym
AFOHeel
Enrollment
40
Registered
2021-03-16
Start date
2019-11-07
Completion date
2027-01-01
Last updated
2025-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases, Musculoskeletal Injury, Peripheral Nervous System Diseases

Keywords

Gait Analysis, Ankle Foot Orthosis, Biomechanics

Brief summary

The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.

Detailed description

In this study the investigators to evaluate the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. Two groups of subjects with impairments below the knee, that result in functional deficits and require daily AFO use, will be recruited for this study. The first group will have unilateral deficits associated with musculoskeletal injury or disease (Group 1), and the second group will have bilateral or unilateral deficits associated with peripheral nervous system disease (Group 2). Lower limb forces and body motion will be assessed using computerized motion capture and force plates in the floor, as individuals walk over-ground. Small reflective markers placed on the participant's skin and force measuring plates in the floor will be used. Participants will walk with their clinically provided AFO, with added heel cushions of two different heights and stiffness's (4 conditions) at a controlled velocity and self-selected velocity. If able, they will walk without their AFO at a self-selected pace. Participants will be asked to provide information regarding their health condition and opinions of the conditions tested.

Interventions

DEVICETall Soft

Tall heel wedge made of soft foam

DEVICETall Firm

Tall heel wedge made of firm foam

DEVICEShort Soft

Short heel wedge made of soft foam

DEVICEShort Firm

Short heel wedge made of firm foam

Sponsors

University of Iowa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Participants will be blinded to the heel wedge conditions.

Intervention model description

Participants will be evaluated in their clinically configured AFO and without an AFO if able. They will also complete evaluation with four provided heel wedge conditions in randomized order: tall soft, tall firm, short soft, short firm.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

GROUP 1 Patient Inclusion criteria * Ages: 18-70 * Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and/or nerve injury, ankle arthritis) * Greater than 2 weeks using their current AFO * Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.) * Ability to walk at a slow to moderate pace * AFO fits into traditional footwear * Able to read and write in English and provide written informed consent GROUP 1 Patient

Exclusion criteria

* Pain \> 6/10 while walking during testing or an increase in pain during testing of \> 2/10. * Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity). * Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth). * Limited contralateral lower limb function due to injury or neurological/musculoskeletal disorder. * Use of a hinged/articulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist/stop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot. * Use of an AFO that crosses the knee (Knee brace) * Insufficient space in shoe to accommodate the tallest heel wedge and their AFO * Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing * Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study. * Body Mass index \> 40. GROUP 2 Patient Inclusion Criteria * Ages: 18-70 * Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes) * Greater than 2 weeks using their current AFO (unilateral or bilateral) * Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.) * AFO fits into traditional footwear * Ability to walk at a slow to moderate pace * Able to read and write in English and provide written informed consent GROUP 2 Patient

Design outcomes

Primary

MeasureTime frameDescription
Participant wedge preferenceBaselineThe participant will rank order their preference for their Clinical AFO, Tall Soft, Tall Firm, Short Soft, or Short Firm wedge on a questionnaire.
Center of pressure velocity timingBaselineTiming of peak center of pressure velocity (percent stance) during gait.
Center of pressure velocity magnitudeBaselineMagnitude of peak center of pressure velocity (m/s) during gait.
Modified Socket Comfort Score (Comfort)BaselineComfort scores range from 0 = most uncomfortable to 10 = most comfortable.
Modified Socket Comfort Score (Smoothness)BaselineSmoothness scores range from 0 = least smooth to 10 = most smooth.
Numerical Pain Rating ScaleBaselinePain will be assessed using a standard 11-point numerical pain rating scale, in which 0 = no pain and 10 = worst pain imaginable.

Secondary

MeasureTime frameDescription
Ankle Range of MotionBaselineAnkle range of motion (degrees) during gait.
Peak Ankle MomentBaselinePeak ankle moment (Nm/kg) during gait.
Peak Ankle PowerBaselinePeak ankle power (W/kg) during gait.

Other

MeasureTime frameDescription
PROMIS Patient reported outcomes for physical functionBaselineThe Patient Reported Outcome Information System (PROMIS) physical function Computer Adaptive Test (CAT) is a computerized assessment measuring physical function. It is scored using a T-score in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. In a given PROMIS domain, a T-score above 50 represents more of the measured variable than the population average.
Activities-Specific Balance Confidence (ABC)BaselineThe ABC provides a standardized evaluation of balance confidence across a range of common daily tasks.

Countries

United States

Contacts

Primary ContactJason M Wilken, PT, PhD
jason-wilken@uiowa.edu319-335-6857
Backup ContactKirsten M Anderson, PhD
kirsten-m-anderson@uiowa.edu319-353-0431

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026